ZYGEL
Dead / Abandoned — Abandoned — no statement of use filed (as of 07 Mar 2022)
What this means for you
This application is over — abandoned 07 Mar 2022. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 87571145
- Mark type
- Stylized text
- Filed
- 16 Aug 2017
- Published for opposition
- 26 Dec 2017
- Abandoned
- 07 Mar 2022
- Attorney of record
- Sarah Anne Keefe
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of human and veterinary diseases and disorders, namely, addiction, auditory diseases and disorders, autism, autoimmune diseases and disorders, anxiety, bone diseases and disorders, cardiovascular diseases and disorders, cardiopulmonary diseases and disorders, cognitive diseases and disorders, dermatological diseases and disorders, diabetic diseases and disorders, endocrine diseases and disorders, gastroenterological diseases and disorders, genetic diseases and disorders, genitourinary diseases and disorders, hepatological diseases and disorders, hormonal diseases and disorders, infectious diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, metabolic diseases and disorders, movement diseases and disorders, muscular diseases and disorders, musculoskeletal diseases and disorders, neurodegenerative diseases and disorders, neurodevelopmental diseases and disorders, oncological diseases and disorders, ophthalmic diseases and disorders, pain, post-traumatic stress, pulmonary diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, rheumatological diseases and disorders, psychiatric diseases and disorders, seizure diseases and disorders, sexual dysfunction, speech disorders and diseases, traumatic brain injury, and viral diseases and disorders; Pharmaceutical preparations for the treatment of fragile x syndrome, substance related addiction, autism and autism spectrum disorders, epilepsy, seizure diseases and disorders, anxiety, aphasias, stuttering, post-traumatic stress disorder; all of the foregoing specifically excluding narcolepsy and management of sleep disorders
Owner
- Zynerba Pharmaceuticals, Inc., Devon, PA, US
- Zynerba Pharmaceuticals, Inc., Devon, PA, US
Prosecution history
- 07 Mar 2022 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 07 Mar 2022 — ABANDONMENT - NO USE STATEMENT FILED
- 13 Jul 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Jul 2021 — SOU EXTENSION 5 GRANTED
- 30 Jun 2021 — SOU EXTENSION 5 FILED
- 08 Jul 2021 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 30 Jun 2021 — SOU TEAS EXTENSION RECEIVED
- 06 Jan 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Jan 2021 — SOU EXTENSION 4 GRANTED
- 04 Jan 2021 — SOU EXTENSION 4 FILED
- 04 Jan 2021 — SOU TEAS EXTENSION RECEIVED
- 10 Jun 2020 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 08 Jun 2020 — SOU EXTENSION 3 GRANTED
- 08 Jun 2020 — SOU EXTENSION 3 FILED
- 08 Jun 2020 — SOU TEAS EXTENSION RECEIVED